Protein-based cardiogenic shock patient classifier by Rueda, Ferran et al.
..
..
..
..
..
..
Protein-based cardiogenic shock patient
classifier
Ferran Rueda1,2†‡, Eva Borra`s3,4†, Cosme Garcı´a-Garcı´a1,2, Oriol Iborra-Egea1,2,
Elena Revuelta-Lo´pez1,2, Veli-Pekka Harjola5, Germa´n Cediel1,2, Johan Lassus6,
Tuukka Tarvasma¨ki6, Alexandre Mebazaa7, Eduard Sabido´3,4*, and
Antoni Baye´s-Genı´s1,2*
1Heart Institute, Hospital Universitari Germans Trias i Pujol, c/ Canyet SN, 08916 Badalona, Spain; 2Department of Medicine, CIBERCV, Autonomous University of Barcelona,
Barcelona, Spain; 3Proteomics Unit, Centre de Regulacio´ Geno`mica (CRG), Barcelona Institute of Science and Technology (BIST), Dr Aiguader 88, Barcelona, Spain; 4Universitat
Pompeu Fabra (UPF), Dr Aiguader 88, Barcelona, Spain; 5Emergency Medicine, Department of Emergency Medicine and Services, University of Helsinki, Helsinki University
Hospital, Finland; 6Cardiology, University of Helsinki, Heart and Lung Center, Helsinki University Hospital, Finland; and 7U942 Inserm, University Paris Diderot, APHP Hoˆpitaux
Universitaires Saint-Louis-Lariboisie`re, INI-CRCT, Paris, France
Received 11 November 2018; revised 4 January 2019; editorial decision 5 April 2019; accepted 19 April 2019; online publish-ahead-of-print 17 June 2019
See page 2695 for the editorial comment on this article (doi: 10.1093/eurheartj/ehz488)
Aims Cardiogenic shock (CS) is associated with high short-term mortality and a precise CS risk stratification could guide
interventions to improve patient outcome. Here, we developed a circulating protein-based score to predict short-
term mortality risk among patients with CS.
...................................................................................................................................................................................................
Methods
and results
Mass spectrometry analysis of 2654 proteins was used for screening in the Barcelona discovery cohort (n= 48).
Targeted quantitative proteomics analyses (n= 51 proteins) were used in the independent CardShock cohort
(n= 97) to derive and cross-validate the protein classifier. The combination of four circulating proteins
(Cardiogenic Shock 4 proteins—CS4P), discriminated patients with low and high 90-day risk of mortality. CS4P
comprises the abundances of liver-type fatty acid-binding protein, beta-2-microglobulin, fructose-bisphosphate aldo-
lase B, and SerpinG1. Within the CardShock cohort used for internal validation, the C-statistic was 0.78 for the
CardShock risk score, 0.83 for the CS4P model, and 0.84 (P= 0.033 vs. CardShock risk score) for the combination
of CardShock risk score with the CS4P model. The CardShock risk score with the CS4P model showed a marked
benefit in patient reclassification, with a net reclassification improvement (NRI) of 0.49 (P= 0.020) compared with
CardShock risk score. Similar reclassification metrics were observed in the IABP-SHOCK II risk score combined
with CS4P (NRI =0.57; P= 0.032). The CS4P patient classification power was confirmed by enzyme-linked immuno-
sorbent assay (ELISA).
...................................................................................................................................................................................................
Conclusion A new protein-based CS patient classifier, the CS4P, was developed for short-term mortality risk stratification.
CS4P improved predictive metrics in combination with contemporary risk scores, which may guide clinicians in
selecting patients for advanced therapies.
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Introduction
Well into the 21st century, cardiogenic shock (CS) remains associ-
ated with unacceptable high mortality, substantial morbidity, and
resource utilization.1 Despite widespread use of early coronary
reperfusion, CS prevalence remains unaltered in ST-segment eleva-
tion myocardial infarction (STEMI) and it is the leading cause of
in-hospital death.2–4
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Contemporary risk scores are available, including the CardShock
and IABP-SHOCK II risk scores, which mostly rely on classical clinical
acumen and conventional laboratory variables, i.e. lactate and glu-
cose.5,6 However, more accurate risk stratification strategies are
needed for early determination of when palliative or invasive thera-
pies are likely most appropriate or futile in CS.7
Accumulating evidence indicates that CS is not only a pump failure
problem but is rather a systemic inflammatory status within the con-
text of multiorgan failure.8–11 Therefore, comprehensive proteomics
may enable the discovery of novel protein biomarkers that can be
used to acquire pathophysiological knowledge, improve risk stratifi-
cation accuracy, and identify therapeutic targets.12
In the present study, we used quantitative proteomics to identify
and cross-validate a protein-based biomarker combination (the
Cardiogenic Shock 4 Proteins—CS4P) as a new CS risk assessment
score model for short-term mortality. We next tested the CS4P into
enzyme-linked immunosorbent assays (ELISA) to favour its prompt
translation into routine clinical practice (Take home figure).
Methods
Patient cohorts
The Barcelona discovery cohort is a prospective single-centre all-
comers study between March 2011 and March 2015, including con-
secutive patients with STEMI complicated with CS during the first
24 h of evolution. ST-segment elevation myocardial infarction was
defined according to the Third Universal Definition of Myocardial
Infarction.13 Patient management was determined by the physicians,
following guideline recommendations.14,15 Two plasma samples
were obtained (admission and at 24 h) from every patient (n= 48) by
venipuncture and stored at -80C (Supplementary material online,
Figure S1).
The CardShock cohort is a European prospective, multicentre,
multinational study on CS between October 2010 and December
2012, including patients within 6 h from identification of CS with both
acute coronary syndrome (ACS) and non-ACS aetiologies.5 Cohort
clinical characteristics and inclusion and exclusion criteria are
reported elsewhere.5 For the present study, only one plasma sample
withdrawn within 24 h of admission, immediately frozen and stored
at –80C, was used (n= 97) (Supplementary material online, Figure
S1). No significant differences were observed between CardShock
included and non-included patients (absence of biorepository;
Supplementary material online, Table ST1).
Inclusion and exclusion criteria were similar in both studies.5
Briefly, inclusion criteria required systolic blood pressure (SBP) to be
<90 mmHg for 30 min (or there to be a need for vasopressor therapy
to maintain SBP >90 mmHg) and signs of hypoperfusion (altered
mental status, cold periphery, oliguria, or blood lactate >2 mmol/L).
Exclusion criteria were shock caused by ongoing haemodynamically
significant arrhythmias or after cardiac or non-cardiac surgery.
During follow-up, vital status was determined by direct contact
with the patients or their next of kin, or from population and hospital
registers. The clinical endpoint was 90-day mortality.
Both cohorts were approved by local ethics committees at the
participating centres, and studies were conducted in accordance with
the Declaration of Helsinki. Written consent was obtained from the
patients or their next of kin.
Biomarker discovery by screening
proteomics
Quantitative proteomics analysis was performed using mass spec-
trometry (nLC-MS/MS) to identify potential protein biomarker candi-
dates among those proteins differing in abundance between 90-day
survivors and non-survivors. Plasma samples (admission and at 24 h)
from 48 patients of the Barcelona cohort (21 non-survivors and 27
survivors at 90 days) were trypsin digested to peptides and analysed
using label-free screening proteomics (nLC-MS/MS). Details on sam-
ple processing, chromatography separation, mass spectrometry ac-
quisition, and data analysis are provided in Supplementary material
online, Methods. The discovery proteomics data have been deposited
to the ProteomeXchange Consortium with the dataset identifier
PXD011614.
Biomarker cross-validation by targeted
proteomics
Candidate biomarker proteins, identified in the discovery phase,
were evaluated in terms of classification power in the CardShock
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cohort with targeted proteomics quantification using parallel reaction
monitoring (PRM). Plasma samples corresponding to 97 patients
from the CardShock cohort (36 non-survivors and 61 survivors at
90 days), were trypsin digested and analysed using targeted nLC-PRM
and isotopically labelled standard peptides as internal references.
Fragment ion chromatographic traces for precursor peptides were
evaluated, logarithmic transformed, and normalized using the internal
reference peptides. Protein abundances were estimated, and protein
relative quantification was assessed between survivors and non-
survivors. Assay variability was calculated with seven injections of a
mixture of the isotopically labelled reference peptides expanding 3
weeks of the acquisition of the patient samples. Details on sample
processing and PRM are presented in Supplementary material online,
Methods. The targeted proteomics data have been deposited to the
ProteomeXchange Consortium with the dataset identifier
PXD011593.
Enzyme-linked immunosorbent assays of
validated proteins
Four commercially available ELISA kits were used, following the
instructions of the manufacturer, for each validated protein in all
patients from the CardShock cohort. Details on each ELISA assay are
presented in Supplementary material online, Methods.
Statistical analyses
Clinical variables are presented as number (n) and percentage (%) for
categorical variables, mean and standard deviation for normally dis-
tributed variables, or median and interquartile range (IQR) for
skewed variables. Comparisons between groups were performed
using the v2 test, the Student’s t-test, or Mann–Whitney U test as
appropriate.
Protein abundance estimates and relative protein quantification
between groups (survivors vs. non-survivors) from proteomics data
were performed with the software packages Skyline 3.716 and
MSstats 3.8.2 (details in Supplementary material online, Methods).
The best protein combinations for classifying 90-day mortality risk in
patients with CS were challenged within the CardShock cohort,
which was divided into a training subset (two of three patients) and a
validation subset (one of three patients). Within the training set the
abundance of each protein was fitted in a logistic regression model
between survivors and non-survivors, and the classification ability of
each protein was evaluated by the area under the curve (AUC) of a
receiver operating characteristic. The protein with the highest AUC
was selected as the first classifier. Most discriminative proteins were
repeatedly added to the classifier as long as their combination
resulted in an increase of AUC value higher than 0.01. The obtained
protein combination in the training subset was then fitted in a logistic
regression model and was applied on the validation subset. The
described procedure was repeated 500 times to assess the reprodu-
cibility of classification ability, and the final consensus model was com-
prised of the combination of proteins which were selected the most
in the 500 repeats.17
The CardShock risk score, used as baseline model, includes age
>75 years, confusion at presentation, previous myocardial infarction
or coronary artery bypass grafting (CABG), ACS aetiology, left ven-
tricular ejection fraction <40%, blood lactate, and estimated
glomerular filtration rate by the Chronic Kidney Disease
Epidemiology Collaboration formula (eGFRCKD-EPI). Model calibra-
tions were calculated using the Hosmer–Lemeshow test, and patient
discrimination and reclassification were evaluated using the Harrell
C-statistic (AUC) and continuous net reclassification improvement
(cNRI). In the cNRI, we calculated the proportion of non-survivors
that increased their risk probability, and the survivors that decreased
their risk probability by the updated model compared with the base-
line model. Confidence intervals for the C-statistic and the NRI were
obtained by 1000-fold bootstrap resampling. Differences were con-
sidered statistically significant at P< 0.05. Analyses were performed
using STATA V.13.0 (StataCorp, College Station, TX, USA),
PredictABEL R package v1.2,18 and SPSS V.20.0 (IBM Corp, Armonk,
NY, USA).
Results
Discovery of protein biomarker
candidates (Barcelona cohort)
Table 1 shows the clinical, biochemical, and follow-up data from the
Barcelona discovery cohort. The mean age was 69± 13 years, 35%
were women, and 94% were treated with primary percutaneous cor-
onary intervention. Ninety-day mortality was 45.8%.
A total of 2654 proteins were identified by discovery mass
spectrometry-based proteomics, of which 488 were present in over
30% of the patients (Supplementary material online, Table ST2). After
protein relative quantification among the different variables: patient
outcome (survivors and non-survivors) and sampling time (admission,
24 h). A total of 51 proteins were considered for analysis in the inde-
pendent CardShock cohort (Table 2). Briefly, 32 of these proteins
were directly selected from the derivation cohort as they differed be-
tween survivors and non-survivors (P value < 0.05) in one of the fol-
lowing manners: (i) proteins exhibited differential abundance
between survivors and non-survivors either at admission or at 24 h;
and (ii) proteins changed over time (admission vs. 24 h) exclusively
for survivors or non-survivors. Additionally, 19 proteins were also
included in the study based on previous knowledge and clinical
relevance.
Targeted proteomics cross-validation of
circulating biomarker candidates
(CardShock cohort)
The prediction power of short-term mortality among CS patients of
the 51 selected proteins was further assessed in the CardShock co-
hort using targeted proteomics quantification by PRM. Table 1 shows
the characteristics of the CardShock independent cohort. The mean
age was 66± 14 years, 25% were women, and 90-day mortality was
37.1%. The most common cause of CS was ACS (71%) and mainly
driven by STEMI (52%). Compared to the Barcelona Cohort,
CardShock patients exhibited higher rates of prior heart failure (HF)
and myocardial infarction, and lower blood pressure, although a
more favourable biochemical profile, with higher haemoglobin and
lower creatinine, lactate, and glucose levels (Table 1). Samples were
harvested within a range of 21–33 h from detection of shock.
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High-quality mass spectrometry chromatographic profiles were
obtained for 26 targeted proteins (Figure 1) and compared to the cor-
responding internal references for relative protein quantification
(Supplementary material online, Tables ST3 and ST4 and Figures S2
and S3). The assay variability was calculated as coefficient of variation
(CV) and 96.2% of the targeted peptides exhibited a CV <20% being
the highest value 25% (Supplementary material online, Figure S4). The
best protein combinations for classifying 90-day survivors and non-
survivors in CS patients were identified by performing a predictor se-
lection combined with cross-validation as described in the Methods
section. This evaluation resulted in the identification of a 4-protein
combination—the CS4P—with proteins liver-type fatty acid-binding
protein (L-FABP, P07148), beta-2-microglobulin (B2MG, P61769),
fructose-bisphosphate aldolase B (ALDOB, P05062), and SerpinG1
....................................................................................................................................................................................................................
Table 1 Comparison of baseline characteristics, clinical presentation, management, analytical parameters, and out-
come between the Barcelona and CardShock cohorts
Characteristics Barcelona cohort
(n5 48)
CardShock cohort
(n5 97)
P value
Age (years) 68.8 (13.2) 65.7 (14.0) 0.204
Women, n (%) 17 (35.4) 24 (24.7) 0.179
Medical history, n (%)
Hypertension 30 (62.5) 57 (58.8) 0.666
Diabetes 20 (41.7) 29 (29.9) 0.159
Stroke/TIA 6 (12.5) 11 (11.3) 0.838
Prior heart failure 5 (10.4) 22 (22.7) 0.074
Coronary artery disease 12 (25.0) 34 (35.1) 0.221
Previous myocardial infarction 4 (8.3) 24 (24.7) 0.018
Prior PCI 5 (10.4) 16 (16.5) 0.328
Prior CABG 1 (2.1) 6 (6.2) 0.278
Clinical presentation
Acute coronary syndrome, n (%) 48 (100) 69 (71.1) <0.001
STEMI, n (%) 48 (100) 50 (51.5) <0.001
Resuscitated from cardiac arrest, n (%) 15 (31.3) 20 (20.6) 0.159
Mean blood pressure (mmHg) 69 ± 20 57 ± 10 <0.001
Heart rate (b.p.m.) 85 ± 29 92 ± 28 0.167
LVEF (%) 39 ± 13 34 ± 15 0.057
Management, n (%)
Coronary angiography 46 (95.8) 73 (75.3) 0.002
PCI 45 (93.8) 58 (59.8) <0.001
TIMI flow after PCI 0.104
0 0 (0) 3 (5.1)
1 0 (0) 4 (6.8)
2 4 (10.5) 10 (16.9)
3 34 (89.5) 42 (71.2)
CABG 0 (0) 5 (5.3) 0.104
IABP 27 (56.3) 45 (46.4) 0.264
Biochemistry at admission
Haemoglobin (g/L) 118 ± 24 128 ± 25 0.024
Creatinine (mg/dL), median (IQR) 1.6 (1.3–1.9) 1.2 (0.9–1.6) <0.001
eGFRCKD-EPI (mL/min/1.73 m
2) 42 ± 15 63 ± 29 <0.001
Arterial blood lactate (mmol/L), median (IQR) 6.3 (4.6–15.0) 2.5 (1.8–5.6) 0.003
Lactate >5 mmol/L, n (%) 5 (71.4) 26 (26.8) 0.013
Glucose (mmol/L) 16.9 ± 7.3 11.9 ± 6.0 <0.001
Glucose >10.6 mmol/L, n (%) 38 (84.4) 46 (48.4) <0.001
hsTnT (pg/mL), median (IQR) 2116 (869–7690) 1568 (277–3920) 0.068
NT-proBNP (pg/mL), median (IQR) 1945 (558–6984) 3385 (687–9716) 0.142
90-Day mortality, n (%) 22 (45.8) 36 (37.1) 0.313
CABG, coronary artery bypass grafting; eGFRCKD-EPI, estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration formula; hsTnT, high-sensi-
tivity troponin T; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction on admission; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutan-
eous coronary intervention; STEMI, ST-elevation myocardial infarction; TIA, transient ischaemic attack; TIMI, thrombolysis in myocardial infarction.
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Table 2 List of the 51 proteins selected from screening proteomics for targeted cross-validation
Accession Description
Q8N7J2 APC membrane recruitment protein 2 OS = Homo sapiens GN = AMER2 PE = 1 SV = 3
Q5VTU8 ATP synthase subunit epsilon-like protein, mitochondrial OS = Homo sapiens GN = ATP5EP2 PE = 3 SV = 1
P61769 Beta-2-microglobulin OS = Homo sapiens GN = B2M PE = 1 SV = 1
Q9NYQ6 Cadherin EGF LAG seven-pass G-type receptor 1 OS = Homo sapiens GN = CELSR1 PE = 1 SV = 1
P43121 Cell surface glycoprotein MUC18 OS = Homo sapiens GN = MCAM PE = 1 SV = 2
Q92496 Complement factor H-related protein 4 OS = Homo sapiens GN = CFHR4 PE = 1 SV = 3
O14733 Dual specificity mitogen-activated protein kinase kinase 7 OS = Homo sapiens GN = MAP2K7 PE = 1 SV = 2
O60941 Dystrobrevin beta OS = Homo sapiens GN = DTNB PE = 1 SV = 1
P07148 Fatty acid-binding protein, liver OS = Homo sapiens GN = FABP1 PE = 1 SV = 1
P05062 Fructose-bisphosphate aldolase B OS = Homo sapiens GN = ALDOB PE = 1 SV = 2
A6NHX0 GATS-like protein 2 OS = Homo sapiens GN = GATSL2 PE = 2 SV = 3
P00739 Haptoglobin-related protein OS = Homo sapiens GN = HPR PE = 2 SV = 2
P18065 Insulin-like growth factor-binding protein 2 OS = Homo sapiens GN = IGFBP2 PE = 1 SV = 2
Q13094 Lymphocyte cytosolic protein 2 OS = Homo sapiens GN = LCP2 PE = 1 SV = 1
Q14833 Metabotropic glutamate receptor 4 OS = Homo sapiens GN = GRM4 PE=2 SV = 1
Q5T6S3 PHD finger protein 19 OS = Homo sapiens GN = PHF19 PE = 1 SV = 1
Q9Y285 Phenylalanine—tRNA ligase alpha subunit OS = Homo sapiens GN = FARSA PE = 1 SV = 3
O60879 Protein diaphanous homologue 2 OS = Homo sapiens GN = DIAPH2 PE = 1 SV = 1
P78504 Protein jagged-1 OS = Homo sapiens GN = JAG1 PE = 1 SV = 3
P05109 Protein S100-A8 OS = Homo sapiens GN = S100A8 PE = 1 SV = 1
P20848 Putative alpha-1-antitrypsin-related protein OS = Homo sapiens GN = SERPINA2 PE = 1 SV = 1
Q2PPJ7 Ral GTPase-activating protein subunit alpha-2 OS = Homo sapiens GN = RALGAPA2 PE = 1 SV = 2
P02753 Retinol-binding protein 4 OS = Homo sapiens GN = RBP4 PE = 1 SV = 3
Q6XE24 RNA-binding motif, single-stranded-interacting protein 3 OS = Homo sapiens GN = RBMS3 PE = 1 SV = 1
P49908 Selenoprotein P OS = Homo sapiens GN = SEPP1 PE = 1 SV = 3
Q99835 Smoothened homologue OS = Homo sapiens GN = SMO PE = 1 SV = 1
P50225 Sulfotransferase 1A1 OS = Homo sapiens GN = SULT1A1 PE = 1 SV = 3
Q5SNT2 Transmembrane protein 201 OS = Homo sapiens GN = TMEM201 PE = 1 SV = 1
Q8N655 Uncharacterized protein C10orf12 OS = Homo sapiens GN = C10orf12 PE = 1 SV = 1
Q9Y4I1 Unconventional myosin-Va OS = Homo sapiens GN = MYO5A PE = 1 SV = 2
Q9NZ43 Vesicle transport protein USE1 OS = Homo sapiens GN = USE1 PE = 1 SV = 2
Q15878 Voltage-dependent R-type calcium channel subunit alpha-1E OS = Homo sapiens GN = CACNA1E PE = 1 SV = 3
P01011 Alpha-1-antichymotrypsin OS = Homo sapiens GN = SERPINA3 PE = 1 SV = 2
P01019 Angiotensinogen OS = Homo sapiens GN = AGT PE = 1 SV = 1
P02741 C-reactive protein OS = Homo sapiens GN = CRP PE = 1 SV = 1
P02671 Fibrinogen alpha chain OS = Homo sapiens GN = FGA PE = 1 SV = 2
P02675 Fibrinogen beta chain OS = Homo sapiens GN = FGB PE = 1 SV = 2
P02679 Fibrinogen gamma chain OS = Homo sapiens GN = FGG PE = 1 SV = 3
P05546 Heparin cofactor 2 OS = Homo sapiens GN = SERPIND1 PE = 1 SV = 3
P05121 Plasminogen activator inhibitor 1 OS = Homo sapiens OX = 9606 GN = SERPINE1 PE = 1 SV = 1
P00747 Plasminogen OS = Homo sapiens GN = PLG PE = 1 SV = 2
P00488 Coagulation factor XIII A chain OS = Homo sapiens GN = F13A1 PE = 1 SV = 4
Q01638 Interleukin-1 receptor-like 1 OS = Homo sapiens OX = 9606 GN = IL1RL1 PE = 1 SV = 4
P16860 Natriuretic peptides B OS = Homo sapiens OX = 9606 GN = NPPB PE = 1 SV = 1
P45379 Troponin T, cardiac muscle OS = Homo sapiens OX = 9606 GN = TNNT2 PE = 1 SV = 3
P19429 Troponin I, cardiac muscle OS = Homo sapiens OX = 9606 GN = TNNI3 PE = 1 SV = 3
P62979 Ubiquitin-40S ribosomal protein S27a OS = Homo sapiens OX = 9606 GN = RPS27A PE = 1 SV = 2
P04075 Fructose-bisphosphate aldolase A OS = Homo sapiens OX = 9606 GN = ALDOA PE = 1 SV = 2
P04040 Catalase OS = Homo sapiens OX = 9606 GN = CAT PE = 1 SV = 3
P05155 Plasma protease C1 inhibitor OS = Homo sapiens OX = 9606 GN = SERPING1 PE = 1 SV = 2
P04114 Apolipoprotein B-100 OS = Homo sapiens OX = 9606 GN = APOB PE = 1 SV = 2
2688 F. Rueda et al.
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Figure 1 Targeted proteomics results. (A) Targeted mass spectrometry chromatographic profiles corresponding to the endogenous peptides and
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.(IC1, P05155), as the best protein classifier to identify short-term
mortality risk with an AUC of 0.83 (95% CI 0.74–0.89) (Table 3 and
Figure 2).
An additional model was constructed by combining the
CardShock risk score with the new CS4P model (CardShock þ
CS4P). The CardShockþCS4P significantly improved the C-statistics
for mortality prediction compared with the CardShock risk score
alone (AUC 0.84 vs. 0.78, P= 0.033; Table 3 and Figure 2).
Furthermore, the CardShock þ CS4P showed a marked benefit in
patient reclassification, with an NRI of 0.49 (P= 0.020) (Table 3;
Supplementary material online, Figures S5 and S6). Overall,
CardShock þ CS4P resulted in an improved reclassification com-
pared to CardShock risk score. Among survivors, 64% were down-
classified and 60% up-classified using the combined CardShock þ
CS4P.
Baseline and 24 h samples of the Barcelona cohort were analysed
in four temporal strata relative to sample collection (00:00–6:00 h,
6:00–12:00 h, 12:00–18:00 h, and 18:00–00:00 h). Samples were
drawn in the same temporal distribution among survivors and non-
survivors and abundance of the CSP4 proteins (measured by MS;
Supplementary material online, Table ST3) was not significantly differ-
ent in the four temporal strata in both survivors and non-survivors.
Taken together, these data suggest a small relevance of the circadian
pattern in the reported data.
In an exploratory analysis, we also combined the CS4P model with
another contemporary risk score, the IABP-SHOCK II,6 generating
the IABP-SHOCK II þ CS4P (Table 3). The IABP-SHOCK II þ CS4P
also provided better prediction metrics compared to IABP-SHOCK
II, with improved C-statistics (AUC 0.80 vs. AUC 0.78) and NRI of
0.57 (P= 0.032).
Translation of CS4P into enzyme-linked
immunosorbent assays (ELISA)
The CS4P model defined by targeted proteomics was tested by
ELISA to support its prompt translation into routine clinical prac-
tice. Median (IQR) circulating concentrations of the studied pro-
teins were L-FABP, 160 pg/mL (42–1720 pg/mL); B2MG, 482mg/
mL (276–752mg/mL); ALDOB, 101 ng/mL (70–209 ng/mL); and
IC1, 218 pg/mL (169–259 pg/mL), respectively. Circulating L-FABP
(453 vs. 94 pg/mL, P= 0.02), B2M (709 vs. 344mg/mL, P< 0.001),
and ALDOB (156 vs. 84 ng/mL, P= 0.05) were higher in non-
survivors relative to survivors. By contrast, IC1 concentration was
significantly lower in non-survivors relative to survivors (205 vs.
226 pg/mL, P= 0.02) (Figure 3, Supplementary material online,
Table ST5).
Protein concentrations of the CS4P obtained by ELISA combined
with the CardShock risk score provided an AUC of 0.82 (95% CI
0.73–0.90), not significantly different than that obtained by targeted
proteomics (P= 0.123) (Supplementary material online, Figures S7
and S8).
Discussion
In the present study, we performed quantitative proteomics analyses
in two independent CS cohorts for the discovery and cross-
validation of CS biomarkers. First, we used discovery mass spectrom-
etry to quantify thousands of different proteins without the need of
previous knowledge, and thus identify proteins not previously associ-
ated to CS. After protein relative quantification between survivors
and non-survivors the classification power of a total of 51 proteins
was further evaluated in an independent cohort by targeted proteo-
mics and cross-validation. We identified four proteins (L-FABP,
B2MG, ALDOB, and IC1) for which the measured levels within 24 h
of CS admission substantially improved risk prediction beyond estab-
lished contemporary clinical risk scores (Take home figure). Based on
the results, we developed a protein-based classifier—the CS4P—
which was also tested by ELISA, that accurately discriminates patients
according to their short-term mortality risk.
Despite the generalization of early reperfusion and modern inten-
sive care, CS management remains challenging with mortality rates of
40%.19 Early and accurate risk stratification is crucial for prompt
identification of the sickest patients who may benefit from advanced
therapies. While clinical predictors of adverse outcome have been
well-known for decades, their derivation from pre-percutaneous cor-
onary intervention (PCI) clinical trials and a lack of external validation
precluded their routine use and prompted the development of more
contemporary risk classifiers. Two scores have been recently
reported. The CardShock risk score5 was developed from a large
prospective multicentre European registry of unselected CS patients
with a broad spectrum of aetiologies (two-thirds STEMI). The
....................................................................................................................................................................................................................
Table 3 Comparison of model performances for predicting 90-day mortality in cardiogenic shock patients
AUC HL P-value NRI Threshold
(Youden’s J)
Sensitivity Specificity
CardShock 0.78 (0.69–0.87) 3.29 0.914 – 0.25 0.91 0.54
IABP-Shock IIa 0.78 (0.66–0.90) 6.64 0.576 – 0.26 0.85 0.58
CS4P 0.83 (0.74–0.89) 13.26 0.103 – 0.36 0.83 0.75
CardShock þ CS4P 0.84 (0.76–0.93) 7.25 0.509 0.49 0.47 0.77 0.84
IABP-Shock II þ CS4P 0.80 (0.67–0.92) 3.44 0.904 0.57 0.35 0.85 0.68
CardShock includes age >75 years, confusion at presentation, previous myocardial infarction, or CABG, ACS aetiology, LVEF <40%, blood lactate, and eGFRCKD-EPI. CS4P score
includes liver-type fatty acid-binding protein, fructose-bisphosphate aldolase B, beta-2-microglobulin, and SerpinG1. CardShock þ CS4P includes CardShock plus CS4P score.
AUC, area under the curve; HL, Hosmer–Lemeshow; NRI, net reclassification improvement.
aIABP-SHOCK II scores (n= 55) were calculated from the CardShock database, as previously reported.6
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..IABP-SHOCK II risk score6 was developed from IABP-SHOCK II trial
participants and is specific for PCI-treated STEMI-related CS. These
two scores are externally validated (of note, the IABP-SHOCK II risk
score was validated by the CardShock risk score used here) and in-
clude classical clinical and biochemical variables for short-term risk
stratification.
Notably, the laboratory parameters included in these risk scores
are basic biochemical tests—glucose and lactate—that have been
routinely used in the clinic for several decades, but also include clinic-
al acumen parameters. More recent studies have explored cardiac
and extra-cardiac predictive biomarkers in CS.8–11,20 However, most
of these studies are small or not validated by external cohorts or did
not assess the incremental predictive value of such biomarkers com-
bined with current clinical practice. Particularly, novel renal bio-
markers, including cystatin C, plasma neutrophil gelatinase-associated
lipocalin, and kidney injury molecule-1, have not performed better
than conventional creatinine.21 With regards to proteomics data in
other cardiovascular pathology contexts, a proteomics approach was
recently reported in the setting of stable coronary artery disease, in
which a 9-protein risk score was reported with a C-statistic of 0.74.22
To our knowledge, this is the first study to employ a comprehen-
sive quantitative proteomics approach combined with targeted
proteomics to discover and validate risk assessment molecular bio-
markers in CS. Our results showed that the combination of four cir-
culating proteins (L-FABP, ALDOB, B2MG, and IC1), measured
within 24 h of admission, produced the CS4P molecular classifier cap-
able of distinguishing high-risk CS patients with a C-statistic of 0.83
for short-term mortality. This discrimination performance is at least
as high as that provided by contemporary CS risk scores (CardShock
and IABP-SHOCK II risk scores) and importantly, improved their per-
formance. The translation of the CS4P at the patients’ bedside should
be the next logical step, but it will likely require future refinements of
the ELISA immunoassays used here. At present, only B2MG has avail-
able assays validated for clinical use with FDA and CE mark. Relative
to ALDOB and IC1 and L-FABP, the ELISA assays used in this study
were for research use only. Nevertheless, these assays were robust
and reproducible, and their validation for clinical use may be achieved
in the near future. Whether a CS4P biomarker-guided approach may
be of value in the setting of CS must be explored in appropriately
conducted prospective randomized clinical trials.
In addition to their value as biomarkers, the four proteins identified
in this study provide a better understanding of the pathophysiology
of CS and multi-organ damage. Remarkably, L-FABP, ALDOB, and
B2MG were significantly higher among non-survivors, while IC1 was
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Figure 2 Improvement in discrimination for prediction of 90-day mortality risk with each model. CardShock risk score includes age >75 years,
confusion at presentation, previous myocardial infarction or coronary artery bypass grafting, ACS aetiology, LVEF <40%, blood lactate, and
eGFRCKD-EPI. CS4P score includes circulating protein abundance measured by parallel reaction monitoring of the liver-type fatty acid-binding protein,
the Fructose-bisphosphate aldolase B, the beta-2-microglobulin, and the SerpinG1. CardShockþ CS4P includes CardShock risk score plus the CS4P
score. AUC values for CS4P, CS4Pþ CardShock, and CardShock are 0.83, 0.84, and 0.78, respectively, and are indicated in brackets in the receiver
operating characteristic plot. The Mann–Whitney test was used for statistical assessment.
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significantly reduced in non-survivors relative to survivors, respect-
ively. Liver-type fatty acid-binding protein is a cytosolic protein that
participates in the intracellular transport of fatty acids to the mito-
chondria; binds reactive oxygen species; and is involved in intracellu-
lar signalling pathways, cell growth, and differentiation. Liver-type
fatty acid-binding protein is present in the liver, intestine, stomach,
lung, and kidney, and its expression is up-regulated by tissue injury.
Circulating L-FABP shows an early and fleeting elevation in septic
shock, which indicates liver injury and is associated with adverse out-
comes.23 Matsumori et al.24 found that in patients with ACS high
L-FABP may be useful in identifying high-risk patients for future car-
diovascular events. In another study, Hishikari et al.25 examined 281
consecutive patients with acutely decompensated HF and found that
L-FABP is useful for predicting the onset of acute kidney injury.
Indeed, L-FABP is involved in acute kidney tubular necrosis and
chronic kidney failure.
Fructose-bisphosphate aldolase B is a key component of the gly-
colysis and gluconeogenesis pathways and is mainly expressed in the
cortex of kidneys, liver, and small intestine Peyer’s Patch. It is involved
in hereditary fructose intolerance and Bardet–Biedl Syndrome.
Serum ALDOB levels appear to be a useful measure of liver cell
necrosis in both benign and malignant liver diseases.26 Fructose-
bisphosphate aldolase B is up-regulated during the first 4 h in a
murine experimental septic shock model.27 Fructose-bisphosphate
aldolase B has also been related to obesity, liver inflammation, and
hepatic fibrosis, consistent with a multiorgan damage scenario.
Beta-2-microglobulin is a well-known small protein expressed
on the surface of nearly all nucleated cells and in most biological
fluids. B2M plays an important role in antigen presentation, iron
ion homoeostasis, and erythrocyte differentiation regulation.
Abnormal forms of B2M are involved in amiloydosis, retinitis pig-
mentosa, immunodeficiency 43, multiple sclerosis, and thrombo-
cytopenia. Beta-2-microglobulin has recently been proposed as a
marker of worsening renal function and acute HF.28,29 Beta-2-
microglobulin is elevated in coronary artery disease and other
forms of atherosclerosis and correlates with disease severity inde-
pendently of other risk factors.30,31
Finally, IC1 is an alpha-globulin that regulates not only the comple-
ment system but also the plasma kallikrein–kinin, fibrinolytic, and co-
agulation systems. The biologic activities of IC1 can be divided into
the regulation of vascular permeability and anti-inflammatory func-
tions. IC1 is mainly present in lungs, liver, subcutaneous adipose tis-
sue, and kidneys, and it has been shown to play a cardioprotective
role after myocardial ischaemia and reperfusion.32,33 Fattouch et al.34
found that the inhibition of the classic complement pathway by IC1
appeared to be an effective mean of preserving ischaemic myocar-
dium from reperfusion injury. This led to suggest that IC1 administra-
tion might be a rescue therapy in STEMI. Furthermore, Thielmann et
al.35 demonstrated that IC1 administration in emergency CABG with
acute STEMI was safe and effective to inhibit complement activation
and may reduce myocardial ischaemia–reperfusion injury. More re-
cently, IC1 treatment has also been postulated to counteract myo-
cardial infarction-induced inflammation in a rat model.36 These data
are consistent with our findings of increased IC1 levels among CS sur-
vivors. In another line of evidence, it has been reported that patients
with more severe forms of septic shock could exhibit a relative
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deficiency of IC1,37 also in agreement with our findings in patients
with CS.
Little is known about physiological factors affecting release variabil-
ity of neither the identified proteins nor its kinetics in pathologic con-
ditions. Beta-2-microglobulin and IC1 are not affected by the
circadian rhythm. Actually, B2MG is used as a gold standard for refer-
ence genes that are stable and not affected by experimental condi-
tions.38 Fructose-bisphosphate aldolase B and L-FABP showed a
weak circadian rhythm in murine models,39 but no evidence reported
in humans. Relative to fasting conditions, B2MG, ALDOB, and IC1
are not affected by fasting condition.38 Liver-type fatty acid-binding
protein was found regulated by fasting-feeding cycles in rats.39 Lastly,
relative to drug intake, ALDOB, L-FABP, and IC1 have no drug inter-
action. The only approved drug proven to interact with B2M is
opium-derivatives. However, only a binding has been proposed, with
no pharmacological action described.
Overall, these four proteins reflect multiorgan dysfunction, as well
as systemic inflammation and immune activation.23–37 During the
early hours of CS, changes in the expression of these proteins may
precede overt multiorgan failure and identify patients at a higher mor-
tality risk. These data highlight the relevance of systemic involvement
in CS, beyond primary pump failure. It may be speculated that the
same pathways might be activated in the sickest patients suffering
from non-cardiac shock.
This study is not without limitations. Both the Barcelona and
CardShock cohorts were modestly sized but are in line with most CS
literature on biomarkers. Indeed, CS cohorts with circulating sample
biobanking are rare. Notably, both cohorts included very few patients
with ventricular-assist devices (one in each cohort), and thus no sub-
analyses were performed in these patients. Although this may not
correspond to the growing current clinical practice, it permits the
analysis of the highest-risk patients when managed using conventional
therapies, and thus may be useful for guiding the selection of candi-
dates for advanced therapies. Finally, the sickest patients, those who
die in the first hours, may be underrepresented due to the
well-known difficulty of enrolment in critical situations. Future larger
studies are needed to validate the scientific premise and estimate
thresholds for clinical application.
Conclusion
Quantitative proteomics analyses in two independent cohorts of CS
patients resulted in the definition of the CS4P risk assessment model, a
circulating four-protein classifier (L-FABP, ALDOB, 2BMG, and IC1)
that improves CS patient stratification according to short-term mortal-
ity risk. Additionally, the combination of the CS4P model to existing risk
scores improved their overall performance predictive metrics, which
may help clinicians in the early identification of high-risk CS patients for
prompt invasive procedures, such as mechanical circulatory support.
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